

Queensland Paediatric Respiratory Syncytial Virus (RSV) Prevention Program: Update and Program Impact



Program outcomes

48% reduction in RSV hospitalisations in infants under 6 months between 15 April and 31 December 2024 (vs. same period 2023)

73% reduction in RSV hospitalisations in infants under 6 months by 17 August 2025 (vs. same period 2023)

More than 1000 RSV hospitalisations prevented for infants under 6 months since the RSV program commenced in QLD




Figure 1: Cumulative RSV hospitalisation among infants aged <6 months, Queensland (1 Jan 2023 to 24 August 2025)
 Source - [Queensland Acute Respiratory Infection Surveillance Report](#)

RSV Immunisation Safety

- RSV immunisation is both safe and effective, with most side effects being mild, such as minor pain or swelling at the injection site.
- Ongoing safety surveillance confirms that RSV immunisation is well tolerated in both infants and during pregnancy, with adverse events comparable to other routine immunisations.

